Medically Integrated Pharmacy

Enhancing Patient-Centered Oncology Care

Through an integrated oncology care model, patients are provided a more comprehensive approach that brings together all aspects of a patient’s cancer treatment—including pharmacy services—within a single, coordinated site of care.

By embedding the pharmacy directly into the oncology practice, patients receive more streamlined, supportive, and effective treatment.

A Medically Integrated Dispensing Pharmacy (MIP) as defined by NCODA is a dispensing pharmacy within an oncology center of excellence that promotes a patient-centered, multidisciplinary team approach.

This innovative approach improves outcomes by providing seamless coordination, personalized support, and comprehensive services—all within the same site of care.

Traditional pharmacy dispensing is defined as the process of medication dispensing activities that occurs separately by a pharmacist from a prescription written by a physician. This dispensing model creates a fragmented approach to cancer care, limiting access to crucial clinical information beyond the prescription and medication list.

As a result, important treatment decisions may be made without a full picture of the patient’s needs, potentially impacting care and outcomes.

Integrated Pharmacy

Compared to Traditional Pharmacy in Oncology

The MIP model addresses these challenges by providing a more integrated and comprehensive approach, ensuring that oncology patients receive the most informed and effective treatment possible.

NCODA, in collaboration with an expert panel of leading oncology healthcare providers, led the development of patient-centered MIP standards to ensure the quality and safety for every patient that is prescribed oral anticancer medications.

These standards were adopted by ASCO and NCODA (Patient-Centered Medically Integrated Dispensing: ASCO/NCODA Standards) and published as the leading guidance for all members of the integrated oncology care team.

Patient-Centered Medically Integrated Dispensing: ASCO/NCODA Standards

READ STANDARDS

Why Medically Integrated Pharmacies Matter

In oncology, access to timely and effective treatment is critical. MIPs are designed to streamline the delivery of oral cancer therapies while enhancing communication between pharmacists, physicians, APPs, nurses, pharmacy technicians, and patients.

RESOURCES

Patient-Centered Care

Improved Medication Adherence

Enhanced Safety and Monitoring

Faster Access and Affordability

Cost Avoidance and Waste Reduction

Improved Patient Education

MIPs address key challenges in cancer treatment by reducing medication abandonment, improving access and affordability, and enhancing adherence. This patient-focused approach ensures timely access to oral anti-cancer medications (OAMs) while providing personalized care and ongoing support.

NCODA’s Pillars of MIP highlight the critical areas that drive better outcomes: abandonment, adherence, access & affordability, time to fill, education, satisfaction, and cost avoidance. By streamlining processes and offering proactive intervention, MIPs help patients stay on track with treatment, minimize financial burdens, and achieve improved overall care.

NCODA Pillars of Medically Integrated Dispensing

View Core Claims

OAM Patient Care

Abandonment

Adherence

Access and Affordability

Time to Fill

Education

Patient Satisfaction

Cost Avoidance

Stories of Impact from Integrated Oncology Practices

Hover to experience

Our Mission

NCODA’s Mission is to support medically integrated pharmacy practices and empower healthcare providers with the tools, resources, and best practices needed to deliver high-quality oncology care. We are dedicated to improving patient outcomes, enhancing medication access, and fostering collaboration across the oncology community.

LEARN MORE

Advancing Quality Cancer Care

Assets & Link

HOME
MEMBER LOGIN
BECOME A MEMBER
Powered by OpenAI